CD79A and Stroke: Notably, the patient maintained stroke-free status for five years on aspirin monotherapy, highlighting the value of antiplatelet therapy in secondary prevention of arterial thrombosis caused by non-criteria antibodies (particularly aβ2GPI IgA) associated APS.